X4 Pharmaceuticals, Inc Stockholders Equity

Quick Answer

X4 Pharmaceuticals, Inc reported Stockholders Equity of $186.29 million for fiscal year 2025.

X4 Pharmaceuticals, Inc Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $186.29M +741.1%
2024 $22.15M -56.7%
2023 $51.10M -31.0%
2022 $74.05M +15.0%
2021 $64.41M -11.5%
2020 $72.80M -43.7%
2019 $129.22M +267.6%
2018 -$77.09M -73.1%
2017 -$44.55M -93.2%
2016 -$23.05M +32.8%
2015 -$34.32M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $61.62M +3.4% +1451.7%
June 30, 2025 $3.97M -95.8% -82.7%
March 31, 2025 $22.94M +2114.7% +3.6%
December 31, 2024 $22.15M -56.7% -62.9%
September 30, 2024 $59.62M -11.8% -36.9%
June 30, 2024 $94.45M +39.9% +9016.9%
March 31, 2024 $1.04M -98.0% -98.0%
December 31, 2023 $51.10M -31.0% -24.4%
  • X4 Pharmaceuticals, Inc showed an increase of +741.1% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2015–2025 period, X4 Pharmaceuticals, Inc’s stockholders equity has grown by 642.8% (from -$34.32 million to $186.29 million).
  • The most recent figure is from X4 Pharmaceuticals, Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment